The effect of carboxymetyl starch (Oozfix) on preventing postoperative complication after gastrectomy: Single-center, non-inferiority, open-label randomized trial

Start Date04 Jul 2022

Sponsor / Collaborator

THE CATHOLIC UNIVERSITY OF KOREA, INCHEON ST. MARYS HOSPITAL

100 Clinical Results associated with THE CATHOLIC UNIVERSITY OF KOREA, INCHEON ST. MARYS HOSPITAL

0 Patents (Medical) associated with THE CATHOLIC UNIVERSITY OF KOREA, INCHEON ST. MARYS HOSPITAL

Literatures (Medical) associated with THE CATHOLIC UNIVERSITY OF KOREA, INCHEON ST. MARYS HOSPITAL

01 Jun 2024·Movement Disorders Clinical Practice

Opicapone to Treat Early Wearing‐off in Parkinson's Disease Patients: The Korean ADOPTION Trial

Article

Author: Sung, Young Hee ; Lee, Ho-Won ; Jeon, Beomseok ; Lee, Jee-Young ; Kim, Sang Jin ; Lee, Phil Hyu ; Park, Mee Young ; Ahn, Tae-Beom ; Lee, Jae-Hyeok ; Shin, Hae-Won ; Kim, Jong-Min ; Kang, Suk Yun ; Park, Jeong-Ho ; Ma, Hyeo-Il ; Lee, Chong Sik ; Cheon, Sang-Myung ; Ferreira, Joaquim J ; Baik, Jong Sam ; Rocha, José-Francisco ; Song, In-Uk ; Choi, Seong-Min ; Kwon, Do Young

AbstractBackgroundIncreasing levodopa (L‐dopa)/dopa decarboxylase inhibitor (DDCI) daily dose or adding a catechol‐O‐methyltransferase (COMT) inhibitor to levodopa/DDCI therapy are strategies used to manage wearing‐off symptoms in Parkinson's disease (PD) patients.ObjectivesTo evaluate the COMT inhibitor opicapone versus an additional dose of levodopa to treat early wearing‐off in PD patients.MethodsADOPTION was a randomized, parallel‐group, open‐label, Phase 4 study conducted in Korea. At baseline, eligible patients were randomized (1:1) to opicapone 50 mg (n = 87) or L‐dopa 100 mg (n = 81) (added to current L‐dopa/DDCI therapy) for 4 weeks. The main efficacy endpoint was change from baseline to end of study in absolute off time. Other endpoints included changes in on time, in Movement Disorder Society‐Unified Parkinson's Disease Rating Scale and 8‐item PD Questionnaire scores, and the Clinical and Patient Global Impression of Improvement/Change.ResultsThe adjusted mean in absolute off time was significantly greater for opicapone 50 mg than for L‐dopa 100 mg (−62.1 vs. −16.7 minutes; P = 0.0015). Opicapone‐treated patients also reported a greater reduction in the percentage of off time (P = 0.0015), a greater increase in absolute on time (P = 0.0338) and a greater increase in the percentage of on time (P = 0.0015). There were no significant differences in other secondary endpoints. The L‐dopa equivalent daily dose was significantly higher in the opicapone group (750.9 vs. 690.0 mg; P = 0.0247), when a 0.5 conversion factor is applied.ConclusionsOpicapone 50 mg was more effective than an additional 100 mg L‐dopa dose at decreasing off time in patients with PD and early wearing‐off.

24 Jan 2024·Journal of Crohn's and Colitis

P457 Small bowel involvement proximal to the terminal ileum is a major risk factor for intestinal resection in patients with small bowel Crohn’s disease

Author: Kim, J S ; Lee, B I ; Lee, K M ; Oh, S N ; Kim, E H ; Oh, C K ; Kim, S W ; Lee, H H ; Cho, Y S ; Choi, H

AbstractBackgroundThe current Montreal classification categorizes Crohn's disease (CD) with small bowel involvement into two groups: L1 and L3. The study aimed to investigate the significance of small bowel involvement proximal to the terminal ileum as a significant risk factor for intestinal resection.MethodsWe conducted a retrospective review of the medical records of Crohn's disease patients diagnosed between January 2001 and December 2020 at Seoul St. Mary's Hospital, St. Vincent Hospital, and Eunpyeong St. Mary's Hospital. The extent of small bowel involvement was independently assessed by two experienced gastrointestinal radiologists using conventional CT, CT enterography, or MR enterography at the time of diagnosis. The terminal ileum was defined as the distal ileal segment within 10 cm from the ileocecal valve and the jejunum was defined as the proximal 1/2 of the small intestine beyond the ligament of Treitz. Radiologic disease activity and fibrostenosis at the time of diagnosis were also scored as 0, 1, and 2 using Maglinte classification, respectively.ResultsOut of 617 CD patients, 346 were included in the study, while 271 were excluded due to radiologic noninvolvement of the small bowel, inadequate or missing radiologic data, initial diagnosis made at another institution, or diagnosis through surgery. Median age at diagnosis was 24 years (range 10-76) and 250 (72.3%) were male. The median follow-up duration was 53 months (4-201). During the follow-up period, 43 patients (12.4%) underwent intestinal resection. Small bowel involvement proximal to the terminal ileum was significantly associated with a higher cumulative risk of intestinal resection (15.4% vs. 3.5%, P=0.006). Neither jejunal involvement or colonic involvement (L3 vs. L1) showed a significant association with cumulative risk of intestinal resection (16.0% vs. 11.1%, P=0.222; 12.4% vs. 12.4%, P=0.773). Radiologic disease activity and fibrostenotic score at the time of diagnosis were significantly associated with the cumulative risk of intestinal resection, respectively (0% vs. 4.4% vs. 19.7%, P<0.001; 8.5% vs. 16.7% vs. 28.2%, P<0.001).ConclusionSmall bowel involvement proximal to the terminal ileum was a major risk factor for requiring intestinal resection in patients with small bowel CD, while jejunal involvement was not. These findings suggest a need for subclassifying small bowel CD.

01 Jan 2024·Yonsei Medical Journal

The Revo-i Robotic Surgical System in Advanced Pancreatic Surgery: A Second Non-Randomized Clinical Trial and Comparative Analysis to the da Vinci™ System

Article

Author: Hwang, Hyeo Seong ; Kang, Chang Moo ; Choi, Munseok ; Kim, Ji Su ; Lee, Woo Jung

PURPOSENumerous robot-assisted pancreatic surgery are being performed worldwide. This study aimed to evaluate the feasibility and safety of the Revo-i robot system (Meerecompany, Seoul, Republic of Korea) for advanced pancreatic surgery, and also compare this new system with the existing da Vinci™ robot system (Intuitive Surgical, Sunnyvale, CA, USA) in the context of robot-assisted pancreaticoduodenectomy (RPD).MATERIALS AND METHODSThis study was a one-armed prospective clinical trial that assessed the Revo-i robot system for advanced pancreatic surgery. Ten patients aged 30 to 73 years were enrolled between December 2019 and August 2020. Postoperative outcomes were retrospectively compared with those of the da Vinci™ surgical system. From March 2017 to August 2020, a total of 47 patients who underwent RPD were analyzed retrospectively.RESULTSIn the prospective clinical trial, pancreaticoduodenectomy was performed in nine patients and one patient underwent central pancreatectomy. Among the 10 study participants, the incidence of major complications was 0% in hospital stay. There were eight postoperative pancreatic fistula (POPF) biochemical leaks (80%). In the retrospective analysis that compared the Revo-i and da Vinci™ robotic systems, 10 patients underwent Revo-i RPD and 37 patients underwent da Vinci™ RPD, with no significant differences in complication or POPF incidence rates between the two groups (p=0.695, p=0.317).CONCLUSIONIn this single-arm prospective study with short-term follow-up at a single institution, the Revo-i robotic surgical system was safe and effective for advanced pancreatic surgery. Revo-i RPD is comparable to the da Vinci™ RPD and is expected to have wide clinical application.

100 Deals associated with THE CATHOLIC UNIVERSITY OF KOREA, INCHEON ST. MARYS HOSPITAL

100 Translational Medicine associated with THE CATHOLIC UNIVERSITY OF KOREA, INCHEON ST. MARYS HOSPITAL

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

THE CATHOLIC UNIVERSITY OF KOREA, INCHEON ST. MARYS HOSPITAL

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 22 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing

THE CATHOLIC UNIVERSITY OF KOREA, INCHEON ST. MARYS HOSPITAL